

Healthcare acquired infections and vaccines – the profile determines everything

LONDON, UK---28th April 2010---ExpertREACT. Healthcare acquired infections (HAIs) continue to be a serious concern to all hospital stakeholders. Beyond increased infection control and stewardship of antibiotic use, the vaccine industry is taking the possibility of further interventions seriously with major programs now in advanced clinical development. **VacZine Analytics** has analyzed the commercial viability of new “nosocomial vaccines” and discusses the latest issues.

*****NOTE***** This article is available only on a “pay per view” basis or to individual existing **VacZine Analytics** clients who have purchased **MarketVIEW: Staphylococcus aureus** vaccines (CAT No: VAMV002) or **MarketVIEW: Pseudomonas aeruginosa** vaccines (CAT No: VAMV010).



Please visit www.vaccine-analytics/products-expertreact.asp

References and Notes:

*SSI = surgical site infection, RTIs (Pneu) = pneumonias, BSIs = Blood stream infections, UTIs = urinary tract infections. #Global is defined as US, Canada, Major 5 EU, Other EU and Australia.

- 1) HHS Action Plan To Prevent Healthcare-Associated Infections. Department of Health and Human Services. Available at: <http://www.hhs.gov/ophs/initiatives/hai/infection.html>. Accessed April 2010.
- 2) Institute of Medicine. To err is human. Washington: National Academy Press; 1999.
- 3) Klevens RM., et al. Estimating Health Care-Associated Infections and Deaths in US Hospitals 2002. Public Health Reports/ March – April 2007. Vol 122. 160-166. Available at: http://www.cdc.gov/ncidod/dhqp/pdf/hicpac/infections_deaths.pdf. Accessed April 2010
- 4) Available at: http://www.cdc.gov/ncidod/dhqp/pdf/Scott_CostPaper.pdf. Accessed April 2010
- 5) Harbath S., at al. The preventable portion of nosocomial infections. An overview of published reports. J Hosp Infect 2003; 54: 258-266
- 6) Sanofi Pasteur partners with Kalobios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa infections. Available at: http://www.sanofipasteur.com/sanofi-pasteur2/front/index.jsp?siteCode=SP_CORP&codeRubrique=34&codePage=PAG_34_PR01. Accessed April 2010.
- 7) MarketVIEW series. April/May 2010. Published by VacZine Analytics. Please visit: <http://www.vaccine-analytics.com/products-marketview.asp>
- 8) Intercell AG. Corporate Presentation. Q2/H1 2009 Results. August 17th 2009. Available at: <http://www.intercell.com>. Accessed April 2010.

© 2010 VacZine Analytics. All rights reserved.



VacZine Analytics^(R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics^(R) and "the spiral logo" are UK Registered Trademarks, 2009

© 2010 VacZine Analytics. All rights reserved.

